. As ubiquitin and UBLs have the same three-dimensional core structure -the β-grasp fold -it is clear that the different UBL-modification systems have a common ancestry.
For the first few decades after the discovery of ubiquitin in 1975, the evolutionary precursors to the ubiquitin-conjugation system went largely undetected. Ubiquitin itself is regarded as one of the most highly conserved of all eukaryotic proteins 5 , but until relatively recently sequence-comparison algorithms were not sensitive enough to detect any bacterial proteins with amino-acid sequence similarity. This situation has changed considerably in the past few years. First, sequence-comparison methods have become more sophisticated, uncovering unexpected similarities between ubiquitin-pathway components (including ubiquitin) and various bacterial proteins 6 . Second, structure determinations have shown that a ubiquitin-like fold is adopted by many eukaryotic and prokaryotic proteins (or their domains), even when amino-acid sequence similarity to ubiquitin is minimal. Third, mechanistic analysis of the biosynthesis of secondary metabolites and enzyme cofactors such as thiamine (vitamin B 1 ) in prokaryotes has uncovered parallels to the activation and conjugation of UBLs 7 . Together, these studies imply that the ubiquitin system has been 'cobbled together' from a variety of pre-existing parts and pathways that had already undergone considerable diversification in prokaryotes 1, 6 . The diversity of the processes regulated by ubiquitin-protein modification is extraordinary 4, 8 and the consequences of the modification depend on whether the ubiquitin is attached to the protein as a monomer or as polyubiquitin chains ( Fig. 1) . Within the chains, the different ubiquitin-ubiquitin linkages help to dictate the fate of the modified substrate. Often when a substrate protein is coupled to a polyubiquitin chain, it binds to the 26S proteasome, a large multisubunit protease complex that degrades the substrate into small peptides and recycles the ubiquitin tag. This happens for substrates that must be eliminated for proper cell-cycle progression, transcriptional regulation, protein quality control, signal transduction or circadian rhythms. Ubiquitylation is also used in non-proteolytic regulatory mechanisms, such as membrane-protein endocytosis and intracellular trafficking, chromatin-mediated regulation of transcription, DNA repair and the assembly of signalling complexes. In this light, it is not surprising that the list of diseases implicating misregulation of the ubiquitin system is growing steadily, and currently includes many cancers, some severe types of mental retardation (such as Angelman syndrome), neurodegenerative disorders such as Parkinson's disease, Huntington's disease and Alzheimer's disease, and type 2 diabetes 9 . In this Review, I discuss the basic features of UBL conjugation to proteins and how such modifications contribute to cellular regulatory mechanisms. I focus on the probable evolutionary antecedents to eukaryotic UBL-protein conjugation in prokaryotes but do not discuss the evolution of the proteasome as it has been well covered elsewhere 10, 11 . I also look at the parallels between enzymes of the ubi quitin system and those that are responsible for the synthesis of specific small molecules (particularly certain sulphurtransferases). In light of the recent wave of research on these evolutionary and mechanistic questions, it seems appropriate to review some of the advances made.
UBLs and related protein domains
Studies begun in the late 1980s identified an interferon-stimulated gene product of 15 kDa (ISG15) that has significant sequence similarity to ubiquitin and also covalently modifies other proteins 12, 13 . ISG15 turned out to be the first in a number of UBLs found to function as protein modifiers (Table 1) . Despite being the first UBL to be identified, the function of ISG15 is still poorly understood, and its E1-like (ISG15-activating) and E2-like (ISG15-conjugating) enzymes (Box 1) were not identified until much later [14] [15] [16] [17] . These enzymes, like ISG15 itself, are strongly induced by type I interferons. Results from studies of mouse models have indicated that the conjugation of ISG15 to proteins Origin and function of ubiquitin-like proteins Mark Hochstrasser 1 Eukaryotic proteins can be modified through attachment to various small molecules and proteins. One such modification is conjugation to ubiquitin and ubiquitin-like proteins (UBLs), which controls an enormous range of physiological processes. Bound UBLs mainly regulate the interactions of proteins with other macromolecules, for example binding to the proteasome or recruitment to chromatin. The various UBL systems use related enzymes to attach specific UBLs to proteins (or other molecules), and most of these attachments are transient. There is increasing evidence suggesting that such UBL-protein modification evolved from prokaryotic sulphurtransferase systems or related enzymes. Moreover, proteins similar to UBL-conjugating enzymes and UBL-deconjugating enzymes seem to have already been widespread at the time of the last common ancestor of eukaryotes, suggesting that UBL-protein conjugation did not first evolve in eukaryotes.
contributes to antiviral responses, consistent with ISG15 being induced by type I interferons [18] [19] [20] , which are some of the first factors produced by the innate immune system in response to viruses.
Like ubiquitin, nine UBLs have been shown to covalently modify other macromolecules, usually proteins (Table 1) , and several other factors are thought to have this ability. This list of UBLs is probably incomplete. Ubiquitin modifies more than 1,000 different proteins in yeast 21 . Some UBLs, such as SUMO (small ubiquitin-related modifier), might target a similar number and diversity of substrates, but others have a much more limited range of substrates than does ubiquitin 4 . For example, the yeast protein Atg12 seems to have a single target (Atg5), and Atg8 attaches to a specific phospholipid, phosphatidylethanolamine 22 . As noted earlier, most UBL-modification pathways use similar enzymatic mechanisms. The main pathways of protein conjugation seem to have evolved through repeated rounds of duplication and diversification of enzymes and protein modifiers derived from ancient biosynthetic pathways (see below). However, a few unusual UBL-conjugation mechanisms have been proposed for specific UBL pathways. In one of these models, a ubiquitin hydrolase was proposed to be able not only to cleave ubiquitin from substrates but also to work backwards, in effect, and ligate ubiquitin to a protein 23 . Another unconventional model came from the results of sequence analysis of an unusual group of putative self-splicing polyproteins in ciliates 24 . These polyproteins consist of a tandem series of variant UBL domains with interspersed self-splicing bacterial intein-like (BIL) domains; the corresponding genes probably arose from a polyubiquitin-encoding gene that had acquired a sequence encoding the BIL domain.
BIL domains have a serine or cysteine residue at their amino terminus, and they activate a peptide-bond rearrangement in which the upstream peptide acyl chain is transferred from N to O (for serine) or from N to S (for cysteine) on the terminal BIL amino acid. This rearrangement initiates cleavage and self-splicing reactions 24 . The acyl shifts (N→S shifts) triggered by the BIL domains in the BIL-ubiquitin-like (BUBL) proteins might facilitate nucleophilic attack on the resultant thioester by a protein (or other molecule) during autocatalytic processing, leading to ligation of the upstream UBL sequence to the attacking molecule 24 . If the attacking group was a lysine side chain of a protein, the resultant product would be a UBL-protein conjugate similar to those formed through the standard pathway (Box 1), even though no E1 or E2 (or ATP) is involved. Notably, the sequences upstream of the BIL domains in BUBL precursors do not need to be UBLs. Thus, there could be a class of protein modifiers that are not related to ubiquitin but are fused upstream of domains with a similar function to BIL domains.
There are also many ubiquitin-related proteins in which the ubiquitin-like domain (ULD) is part of a larger polypeptide but, usually, is neither processed nor covalently attached to other proteins 1 . Such ULDs confer properties on a protein that are similar to those from a transferable UBL, including the ability to bind to specific target proteins. Some ULDs can be cleaved under specific conditions (and some might even become competent for ligation to other proteins). For example, autocleavage at an internal ULD occurs in the deubiquitylating enzyme USP1 after damage to cells by ultraviolet light. The damage thus leads to inactivation of the enzyme and allows the accumulation of monoubiquitylated proliferating cell nuclear antigen (PCNA), which is required for trans-lesion DNA synthesis 25 . The β-grasp fold shared by all structurally characterized UBLs and ULDs is phyletically widespread and ancient; it may have arisen as an RNA-binding module in a primitive protein-translation system 26 . It has been adapted to a broad array of functions, ranging from a scaffold for various enzymatic activities and iron-sulphur-cluster binding to an adaptor module for specific protein-protein interactions.
Box 1 | The basics of the ubiquitin-conjugation pathway
Ubiquitin (green circles) is a 76-residue polypeptide that is activated and attached to substrate proteins by a series of enzymes (see box figure) . The modification of proteins with ubiquitin-like proteins (UBLs) also follows the same general mechanisms.
Three types of enzyme -E1, E2 and E3 -carry out ubiquitinmodification reactions, including the assembly of polyubiquitin chains (conjugation of additional ubiquitins to a single ubiquitin to form a polyubiquitin chain on some proteins is indicated by the brackets in the image). E1s activate ubiquitin. E2s pick up the ubiquitin by transthiolation from E1 and conjugate it to substrates. E3s then ligate the ubiquitin to the substrate (and in some cases, form an intermediary thioester with ubiquitin before the final transfer to the substrate). All eukaryotes encode multiple isozymes of E2 and E3, up to several dozen E2s and many hundreds of E3s. This allows the modification of many proteins in a highly specific manner, and such modifications are often under strict temporal and spatial control.
Ubiquitin is usually attached to proteins through an amide linkage between its carboxyl terminus and a primary amino group on the acceptor protein 2, 52 . The most common linkages are with the ε-amino group (side chain) of a lysine residue, but linkages can also form with the amino group at the amino terminus of the substrate 70 . In addition, ubiquitin has recently been found to be attached to cysteine, serine and threonine residues in proteins [71] [72] [73] . In ubiquitin polymers, the lysine side chain of one ubiquitin molecule is linked to the C terminus of another ubiquitin molecule, and so on. Ubiquitin contains seven lysine residues, all of which can contribute to such linkages.
Ubiquitin has a glycine residue at its C terminus, and this must be activated before it can form a covalent bond with another protein 2, 52 . Initially, the C terminus is adenylated by E1, with the ubiquitin-AMP adduct remaining bound to the enzyme. A cysteine side chain in E1 then attacks the C terminus of ubiquitin, yielding an E1-ubiquitin thioester intermediate. The activated ubiquitin is subsequently passed to a cysteine residue in the active site of an E2 (ref. 74) . Together with an E3, the E2 catalyses ubiquitylation of the substrate. E3s have a crucial role in recognition of the substrate (although not all UBL pathways require an E3). In the ubiquitin pathway, a different E3 can help to attach ubiquitin molecules to a protein that has already been modified by one or more ubiquitins. Such E3s are sometimes called E4s, particularly when they are thought to extend a polyubiquitin chain. Enzymes known as deubiquitylating enzymes (DUBs) can remove ubiquitin molecules that are attached to proteins. As a result of DUB activities, ubiquitin modifies proteins only transiently 61, 75 . This process of dynamically modifying proteins with ubiquitin and other UBLs creates reversible switches between different functional states of a substrate protein, allowing fine control of numerous cellular pathways. 
Consequences of UBL-protein conjugation
Early work on ubiquitin focused mainly on its role in proteolysis [27] [28] [29] . The 26S proteasome is responsible for the degradation of polyubiquitylated proteins, and direct binding of a polyubiquitin chain to the proteasome can fully account for the observed affinity of model polyubiquitylated proteins for this protease complex 30 . In short, the polyubiquitin chain provides a generic affinity tag that results in tight binding of the proteolytic substrate to the proteasome (Fig. 2) . Multiple poly ubiquitin receptors are present within the proteasome [31] [32] [33] . In addition, polyubiquitin-binding domains are found in mobile shuttling factors that direct polyubiquitylated proteins to the proteasome [34] [35] [36] . Specific interactions between ubiquitin and ubiquitin-binding domains (UBDs) are not limited to the binding of ubiquitylated molecules to the proteasome. A general theme that has emerged over the past decade is that many of the functions of ubiquitin and UBLs are mediated by association with UBDs 37 . For instance, a UBD in the Vps23/TSG101 membrane-protein sorting factor mediates recognition of monoubiquitylated membrane proteins, and several distinct UBDs in the deubiquitylating enzyme Ubp14/USP5 allow it to specifically recognize unanchored polyubiquitin chains. At least 16 structurally distinct UBD classes have been characterized so far, and the domains in these classes vary considerably in size (from ~30 to 150 residues) and tertiary structure 37 . The evolution of these different types of UBD allowed a huge expansion of cellular processes that depend on ubiquitin conjugation in modern eukaryotes.
UBDs usually bind to ubiquitin only weakly 37 . Despite the generally low affinities, mutational studies support the physiological relevance of these associations. Linking multiple ubiquitin moieties into a chain can have marked effects on the affinity or avidity of ubiquitin for target proteins. A good example comes from an analysis of polyubiquitin-proteasome binding 30 . Cecile Pickart and colleagues 30 measured the extent to which the degradation of model substrates was inhibited in the presence of ubiquitin chains of various lengths. Tetrameric chains were strongly inhibitory. By contrast, inhibition was extremely weak in the presence of trimeric chains and undetectable with dimeric chains. The lack of a simple dependence of affinity on the length of the chain implies that formation of a tetrameric chain creates a unique binding determinant that is not present in shorter chains or in monoubiquitin 38 . Of the UBLs, SUMO is the most extensively studied. Analyses of the interactions between SUMO and other proteins confirm and extend many of the ideas about ubiquitin-protein interactions detailed so far, and findings from genetic, biochemical and biophysical studies have converged on a single, non-covalent SUMO-binding element, called the SUMO-interaction motif (SIM) 39 . SIM-bearing peptides as short as nine residues (much shorter than the domains that typically bind to ubiquitin) have dissociation constants of between 5 μM and 10 μM, which is substantially tighter binding than that seen with most known UBDs. The SIM consensus sequence contains a central group of three or four hydrophobic residues, usually with a cluster of acidic residues on one side. The SIM forms a β-strand that sits in a hydrophobic surface depression between the β 2 -strand and α 1 -helix of SUMO; acidic residues at the ends of the SIM interact with basic residues on the SUMO surface 40, 41 . This is the opposite face of the β-grasp fold from that recognized on ubiquitin by most UBDs; the surface recognized is a hydrophobic patch centred on the isoleucine residue at position 44 of ubiquitin. Thus, different UBLs can function analogously as adaptor modules, but the way in which they bind to target proteins need not be the same.
It is clear, therefore, that the conjugation of UBLs to a target protein frequently functions to promote interaction of the target with other proteins. When such modifications enhance a target's interaction with another macromolecule, they usually do so by participating directly in the formation of the binding interface with the target molecule (Fig. 3a) . An interaction can also be modulated by an allosteric change in a targetbinding site induced by the attached UBL (Fig. 3b) . Most known cases of regulation by UBLs fall into the former category, and only a handful operate by the latter 42, 43 . Even if only a small proportion of the cellular protein was modified with a UBL, the altered activity of the protein could be enough to effect a change in physiological state. Such non-covalent UBL-protein interactions tend to be weak, however (as mentioned earlier). Specific binding can be greatly enhanced either by polymerization of the ubiquitin or UBL signal, or by combining the weak binding to the ubiquitin/UBL with additional weak binding sites in the conjugated protein (Fig. 3a, c ). An example of such multivalent binding is the association of SUMO-conjugated RanGAP1 with the nuclear-pore complex; neither SUMO nor RanGAP1 alone can bind tightly to this complex 44 . Given their bulk, another way by which UBLs can exert their function is through steric hindrance: the attached UBL can simply block the binding of one protein to another (or to another part of the same protein) (Fig. 3d) . There are relatively few well-established in vivo examples of this intermolecular inhibitory mechanism. One likely reason is that for such a mechanism to operate effectively, a large proportion of the cellular protein would need to be modified by the UBL. However, for many proteins, only a minuscule amount is observed in conjugate form. In principle, such an inhibitory mechanism could still operate if the small proportion of modified protein were localized to a functionally privileged cellular site or if a transient modification were enough to shift the protein to a new state.
Origins of UBL-protein conjugation
An early clue to the antecedents of UBL-protein conjugation came from the amino-acid sequence of the yeast ubiquitin-activating enzyme E1. E1 was found to have weak, but significant, sequence similarity to MoeB, an Escherichia coli protein that is required for biosynthesis of the molybdenum cofactor (Moco) 45 . But the biochemical function of MoeB was unknown when E1 was sequenced in 1991, so this similarity was not particularly informative. During the late 1990s, however, the protein sequences and catalytic mechanisms of the enzymes used to synthesize Moco (and thiamine) began to be deciphered, and intriguing similarities to ubiquitin activation were noted [46] [47] [48] . Because the thiamine synthesis pathway is present in nearly all bacterial species and Moco synthesis enzymes are also found in a broad range of bacteria, these enzymatic systems are thought to be evolutionarily much more ancient than ubiquitin conjugation 6 .
UBL-related sulphur-carrier proteins
To synthesize the cofactors Moco and thiamine, sulphur atoms need to be inserted into their precursors. A small sulphur-carrier protein (MoaD in Moco synthesis and ThiS in thiamine synthesis) donates the necessary sulphur(s). Sulphur is taken from a thiocarboxylate group formed at the C terminus of these proteins (Fig. 4) . MoaD and ThiS are related and, like ubiquitin, their sequences end with a pair of glycine residues. Conversion of the C-terminal glycine carboxylate to a thiocarboxylate in these proteins is preceded by adenylation of the C terminus by an E1-related enzyme: MoeB for MoaD and ThiF for ThiS [47] [48] [49] . Like ubiquitin, both MoaD and ThiS have a β-grasp fold, despite having minimal sequence similarity to ubiquitin 50, 51 . Therefore, ubiquitin, MoaD and ThiS are structurally related proteins with C termini that are activated through adenylation by homologous E1-like enzymes 52, 53 . In the early 2000s, further insight into the potential evolutionary link between these sulphur-transfer systems and UBL activation came from the discovery of ubiquitin-related modifier 1 (Urm1) (ref. 54 ), a protein first found in Saccharomyces cerevisiae that is related to MoaD and ThiS (Fig. 4, right) . Although S. cerevisiae lacks any Moco-containing enzymes and uses a different mechanism to synthesize thiamine, it does express an E1-related protein, Uba4, which has sequence similarity to ThiF and MoeB. Uba4 binds to Urm1 and stimulates the covalent addition of Urm1 to cellular proteins 54, 55 . These findings indicate that Urm1 and Uba4 function as part of a UBL-protein conjugation system, despite having much closer sequence relatedness to bacterial sulphur-transfer enzymes. However, as discussed below, Uba4 also functions in sulphur transfer, so it could be a bifunctional enzyme 56 . The Urm1-Uba4 system may therefore be a 'molecular fossil' that retains features of the more ancient sulphurtransfer pathway yet can also conjugate UBLs to proteins.
Potential dual function of Urm1
The enzymatic activation of the C termini of UBLs by ATP-dependent E1-related enzymes is analogous to other adenylation reactions such as the activation of amino acids by aminoacyl-tRNA synthetases 2 . For UBLs, the energy of ATP hydrolysis is conserved through the formation of the E1-UBL thioester linkage. However, despite being chemically activated, all of the known UBLs (Table 1 ) except for Urm1 also undergo an energetically neutral transesterification to the thiol of a second enzyme, E2 (Box 1). The one apparent exception to the use of an E1-E2 relay, the Urm1 pathway, has distinct features, which it shares with bacterial sulphur-transfer pathways. Uba4 (the E1 in the Urm1 (Fig. 4) . Rhodanese and several RHD-containing proteins are sulphurtransferases, and they operate by transferring sulphur to targets by way of an intermediate persulphide (S-S-H) on their active-site cysteine residue 57 . Many MoeB-family proteins have a domain organization similar to that of Uba4, with an E1-like domain and, C terminal to this, an RHD. On the basis of these and other considerations, it had been proposed that thiocarboxylate formation in MoaD proceeds through an acyl disulphide intermediate between MoaD and the RHD of the MoeB-related enzyme, and that, by analogy, Urm1 transfer from Uba4 to a substrate involves the RHD in Uba4 (ref. 1). In particular, the Uba4 RHD was suggested to form a transient thioester intermediate with Urm1, which is then transferred directly to the substrate, bypassing the requirement for a separate E2 (Fig. 4) . In S. cerevisiae, the cysteine residue in the RHD is required for Urm1-protein ligation 42 . In 2008, work by Jennifer Schmitz and colleagues 56 showed that the RHD of Uba4 can also form a persulphide and can transfer the terminal sulphur to the C terminus of Urm1 in vitro, generating an Urm1-thiocarboxylate. The E1-domain cysteine residue is not required for this, and the authors found no evidence of a Urm1-Uba4 thioester. Instead, they inferred that the adenylated Urm1 is attacked by a persulphide on the RHD, forming an acyl-disulphide intermediate with Urm1, with subsequent release of the thiocarboxylate. They suggested that this could also be an intermediate in Urm1-protein conjugation A newly discovered function for the Urm1 pathway is in the substitution of S for O at position 2 of the wobble uridine in the anticodon of certain tRNAs, a process that modulates their decoding specificity 58, 59 . Urm1 is required for these thiolation reactions, probably functioning as a sulphur carrier in the form of an Urm1-thiocarboxylate. The degree to which tRNA modification by the Urm1 pathway accounts for the pleiotropic physiological roles of Urm1 remains to be determined. Protein modification with Urm1 might also stimulate tRNA thiolation 59 , but a minimal hypothesis would require only the formation of an Urm1-Uba4 acyl disulphide that resolves into the Urm1-thiocarboxylate, from which the sulphur is ultimately transferred to the tRNA.
Although the conserved E1-domain cysteine in Uba4 is dispensable for Urm1-thiocarboxylate formation in vitro, it is necessary for protein conjugation to Urm1 in vivo 54 . This cysteine could function in reductive cleavage of the Urm1-RHD linkage 56 , but this should stimulate formation of an Urm1 C-terminal thiocarboxylate rather than an Urm1-protein amide linkage. Potentially, either the E1-like cysteine undergoes a persulphide exchange with the RHD, freeing the RHD thiol for attack on the Urm1-adenylate (not shown in Fig. 4 ), or the Urm1-adenylate is directly attacked by a lysine residue in a substrate, although this would not explain the requirement for the two Uba4 active-site cysteine residues. Reductive cleavage of the Urm1-RHD disulphide by the E1-domain active-site sulphydryl group would allow the RHD thiol to be regenerated, potentially making it competent for Urm1-thioester formation. Whether the Urm1-protein ligation mechanism reflects an early precursor to other UBL-conjugation mechanisms is not known. It is conceivable that, during the evolution of UBL-conjugation systems, a distinct E2-like factor could have been coopted, leading to loss of the RHD from the E1 and thereby eliminating the persulphide-thiocarboxylate 'side reaction' . Alternatively, eukaryotic UBL modification pathways may have evolved from a distinct prokaryotic β-grasp proteinmodification system 6 .
Radiation of E2s and UBL-specific proteases
When did the E2-like enzymes arise and when did they first associate with E1-like proteins to form the now nearly universal E1-E2 relay used for UBL-protein conjugation? Earlier sequence searches had not revealed any E2-like proteins in bacteria, but recent surveys have revealed an astonishing number of E2-related sequences in the same DNA neighbourhoods (that is, in presumptive operons, domain fusions or co-regulated genes) as UBL-related, E1-like, or JAMM (JAB1/MPN/ Mov34) metalloprotease coding sequences 6, 60 . In eukaryotes, specific JAMM-class proteases act as deubiquitylating enzymes (DUBs) or UBLspecific proteases (ULPs) 61 . A striking radiation of E2-like proteins therefore seems to have occurred in bacteria concomitant with the diversification of UBL and E1-like proteins. The subfamily most closely related to classical UBL-conjugating E2 enzymes has been proposed to be ancestral to the eukaryotic UBL E2s 60 . Although none of these prokaryotic E2-like proteins has yet been shown to catalyse UBL-substrate modification in conjunction with an E1, these contextual associations suggest that at least some of them will.
DUBs (or ULPs in the case of UBLs), are often necessary for C-terminal processing of UBL precursors and for removing UBLs from their targets (Box 1). Although multiple JAMM enzymes have now been linked by contextual sequence analysis to potential UBL-modification systems in prokaryotes, some JAMM enzymes participate in sulphur-transfer mechanisms rather than in UBL-protein conjugation. For instance, Mycobacterium tuberculosis has an unusual cysteine biosynthetic pathway that involves thiocarboxylate derivatization of CysO, a β-grasp protein, by the E1-related MoeZ protein 62 . The gene for a JAMM enzyme clusters with the gene for CysO, and it probably hydrolyses cysteine from CysO in the final step of cysteine biosynthesis. Synthesis of the sulphur-containing thioquinolobactin siderophore (an iron-chelating compound) in Pseudomonas fluorescens requires a sulphur-carrier protein called QbsE that is related to MoaD and ThiS. QbsE, however, is made in precursor form with two additional amino acids after the diglycine motif 63 . A JAMM protease expressed in the same thioquinolobactin biosynthetic operon cleaves these last two residues from QbsE. Therefore, proteases of the type that eukaryotes use to remove UBLs from protein conjugates might originally have been part of bacterial β-grasp protein-based biosynthetic pathways, just like the UBLs and E1-like (and possibly E2-like) enzymes.
E1-like activation of a non-UBL substrate
The E1-like superfamily of adenylating enzymes catalyses a spectrum of biochemical reactions that goes beyond C-terminal activation of β-grasp proteins. The best evidence for this comes from enterobacteria that synthesize and secrete the small antibiotic microcin C7 (MccC7). MccC7 is a modified heptapeptide encoded by a large E. coli plasmid 64 . An isoasparaginyl moiety at the C terminus of MccC7 has a phosphoramidate linkage to a modified adenylate, and attachment of this modified AMP requires the plasmid-encoded mccB product. MccB is a member of the E1-like enzyme superfamily. Therefore, the substrate of this E1-like enzyme is not a β-grasp protein, and the C-terminal modification chemistry is different from that of the sulphurtransferases described above, even though the initial adenylation of a C-terminal α-carboxylate by the E1-related enzymes is similar. 
Outlook
How much of the diversity of UBL-protein modification or analogous conjugation systems is yet to be discovered? Some UBLs are difficult to recognize by amino-acid sequence comparison, so additional β-grasp/ UBL modifiers might still have been overlooked. The exciting possibility of a multitude of prokaryotic UBL-related protein-modification systems, none of which has been analysed experimentally, was made apparent when contextual sequence analyses suggested the existence of a bevy of bacterial regulons that bring together genes encoding novel β-grasp proteins, E1-like enzymes, E2-like proteins and hydrolases related to those in known UBL systems. Moreover, not all E1-like enzymes act on β-grasp/UBL proteins, so further insight into the ability of such enzymes to modify specific proteins or peptides (or other molecules) can be anticipated. Conversely, there may be intracellular protein-protein conjugation mechanisms that involve neither E1-like adenylating enzymes nor β-grasp proteins, such as intein-mediated protein trans-splicing. Along these lines, a 64-residue protein in M. tuberculosis called Pup (prokaryotic ubiquitin-like protein) has been shown to modify specific proteins in vivo and, remarkably, to target them for degradation by the mycobacterial proteasome 65 . Pup is not a β-grasp/UBL protein, and Pup attachment involves linkage of a substrate lysine to what had originally been a glutamine residue at the Pup C terminus. The terminal Pup glutamine is converted to a glutamate either during or before substrate conjugation. Similar amide-bond-forming reactions are seen with transglutaminases and γ-glutamylcysteine synthetases (involved in glutathione synthesis). In fact, the M. tuberculosis PafA protein, which is required for substrate pupylation 65 , has distant sequence similarity to γ-glutamylcysteine synthetases and glutamine synthetases 66 . Mass spectrometry-based proteomic studies could yield further surprises about protein modification and ligation in vivo. Viewed through this wider lens, protein-protein conjugation can be seen as a multifaceted and nearly universally employed means of cellular regulation, and we are only just starting to understand some of the underlying mechanisms. 
